Volume 2, Issue 2, Pages 121-130 (June 2016) Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease  Jeremy Koppel, Heidy Jimenez, Leslie Adrien, Blaine S. Greenwald, Philippe Marambaud, Ezra Cinamon, Peter Davies  Alzheimer's & Dementia: Translational Research & Clinical Interventions  Volume 2, Issue 2, Pages 121-130 (June 2016) DOI: 10.1016/j.trci.2016.05.003 Copyright © 2016 The Authors Terms and Conditions

Fig. 3 Western blots (WB) performed on frontal cortex of mice treated with haloperidol decanoate (N = 11) or vehicle (N = 9) for 2 weeks. (A) No differences were observed in total AMPK. (B) Activated pGSK-3β was reduced in haloperidol treated mice. (C) The ratio of active/total pAMPK-3β/total AMPK was reduced in haloperidol treated mice, suggesting an inactivation of the kinase. The insert displays typical gel lanes from immunoblots used for quantitative analyses with ImageJ. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2016 2, 121-130DOI: (10.1016/j.trci.2016.05.003) Copyright © 2016 The Authors Terms and Conditions